GlyNAC for Health & Longevity

Evidence Review created on 05/04/2026 using AI4L / Opus 4.7

Also known as: Glycine & N-Acetylcysteine, Glycine & NAC, Gly & NAC

Motivation

GlyNAC is a fixed combination of two amino acids — glycine and N-acetylcysteine — taken together as precursors for the body’s most abundant intracellular antioxidant, glutathione. Tissue glutathione falls steadily with age, and supplying both building blocks at the same time is intended to restore it to youthful levels.

Interest in GlyNAC has grown around a small but striking series of clinical trials in older adults that reported broad improvements in mitochondrial function and physical performance over 16 to 24 weeks. Animal work from the same group has also reported lifespan extension. The combination is inexpensive, generally well tolerated, and has been licensed as a commercial product, though most of the human evidence still comes from a single laboratory.

This review examines the current evidence for GlyNAC supplementation as a health and longevity intervention, covering its mechanism, expected benefits, potential risks, dosing approaches, monitoring strategies, sourcing considerations, and practical considerations relevant to its use.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

A curated set of expert commentary and accessible overviews of GlyNAC’s role in glutathione restoration and healthy aging.

• Supplemental Glycine and Cysteine Restore Glutathione Levels and Correct Several Markers of Aging - Rhonda Patrick

  Plain-language summary of the GlyNAC pilot trial in older adults showing that 24 weeks of glycine plus N-acetylcysteine restored red blood cell glutathione, lowered oxidative stress, and improved mitochondrial function, with explicit caveats on the small sample size.

• AMA #42: Optimizing sleep — bedtime routine, molecule regimen, sleep trackers, sauna, & more - Peter Attia

  Discusses Attia’s nightly use of 2 g of glycine, alongside the GlyNAC research from Baylor College of Medicine showing that combined glycine and NAC supplementation reverses several aging-related defects in older adults, while noting limitations of the existing trial base.

• GlyNAC supplementation reverses aging hallmarks in aging humans - Homa Shalchi

  Press release from the institution leading GlyNAC research, summarizing the 2022 randomized double-blind trial led by Dr. Rajagopal Sekhar and the underlying “Power of 3” rationale (glycine, NAC, and glutathione together).

• Adrenal Fatigue, Glutathione Status, and Rheumatoid Arthritis - Chris Kresser

  Functional-medicine commentary on how glutathione status contributes to chronic illness and how glycine and NAC are used together as precursor strategies to support intracellular GSH (glutathione, the body’s main intracellular antioxidant).

• Glutathione vs. NAC: Which Antioxidant Is Best for Your Liver? - Shayna Sandhaus

  Accessible overview explaining why supplementing glutathione precursors (glycine and NAC) may be more effective than oral glutathione, with practical context on how each compound contributes to antioxidant defense.

Note: Andrew Huberman has not published a stand-alone hubermanlab.com episode page dedicated to GlyNAC. He discusses glycine (notably ~2 g for sleep) and NAC (notably for immune support) in separate contexts rather than as a combined GlyNAC protocol, so no Huberman Lab item is listed here rather than padding with marginally relevant content.

Grokipedia

GlyNAC

Encyclopedic, fact-checked article on GlyNAC covering its composition as a glycine and NAC combination, the clinical research program led by Dr. Rajagopal Sekhar at Baylor College of Medicine, and the evidence for benefits in aging, mitochondrial function, oxidative stress reduction, and lifespan extension in mice.

Examine

GlyNAC benefits, dosage, and side effects

Provides a regularly updated evidence summary of GlyNAC, covering its role as a glutathione precursor combination, dosing used in trials, the evidence in aging, type 2 diabetes, and HIV, and the side-effect profile relative to NAC alone.

ConsumerLab

No dedicated ConsumerLab article for GlyNAC was found. GlyNAC is discussed within ConsumerLab’s NAC (N-Acetyl Cysteine) Supplements Review, which covers the longevity evidence for the glycine + NAC combination and tests commercial NAC and combined products for label accuracy and contamination.

Systematic Reviews

No systematic reviews or meta-analyses for GlyNAC were found on PubMed as of May 4, 2026.

Mechanism of Action

GlyNAC works through a multi-step mechanism centered on restoring intracellular glutathione, the body’s primary antioxidant tripeptide:

• Glutathione synthesis: GSH (glutathione, the body’s main intracellular antioxidant) is built from three amino acids — glutamate, cysteine, and glycine — in two ATP (adenosine triphosphate, the cell’s main energy currency)–dependent steps. The first step is catalyzed by GCL (glutamate–cysteine ligase, the rate-limiting enzyme of GSH synthesis), which combines cysteine and glutamate; the second is catalyzed by glutathione synthetase, which adds glycine. NAC (N-acetylcysteine, a cysteine-precursor amino acid derivative) is hydrolyzed to cysteine in the gut and liver; supplemented glycine adds the second co-limiting substrate. Without both, raising cysteine alone is often insufficient in older adults.

• Oxidative stress reduction: Restored GSH provides the cellular substrate for GPx (glutathione peroxidase, an enzyme family that uses GSH to detoxify peroxides) and other detoxifying systems, lowering oxidative damage to lipids, proteins, and DNA. Markers such as F2-isoprostanes (a urinary marker of lipid peroxidation) and malondialdehyde fall.

• Mitochondrial function restoration: Adequate mitochondrial GSH protects the inner membrane from oxidative damage and supports normal fuel oxidation. In older adults and people with type 2 diabetes, GlyNAC shifts mitochondrial metabolism away from excessive glucose oxidation toward more efficient fatty-acid oxidation.

• Inflammation and insulin signaling: GSH modulates redox-sensitive transcription factors NF-κB (a master inflammation transcription factor) and Nrf2 (a master antioxidant defense transcription factor), reducing chronic low-grade inflammation. Lower oxidative stress in skeletal muscle and liver is associated with improved insulin sensitivity.

• The “Power of 3”: Sekhar describes GlyNAC’s mechanism as a synergy of three components: glycine contributes inhibitory neurotransmitter activity and is a major substrate for collagen and porphyrin synthesis; NAC supplies cysteine and contributes direct thiol-mediated antioxidant effects; restored GSH then provides broad intracellular antioxidant coverage and supports phase II detoxification via GST (glutathione S-transferase, a family of detoxification enzymes). The combined effect addresses more aging-related defects than any single component alone.

• Hallmarks of aging: Trial data report that GlyNAC supplementation improves multiple recognized hallmarks of aging in older adults, including mitochondrial dysfunction, genomic instability, cellular senescence, stem cell fatigue, altered intercellular communication, dysregulated nutrient sensing, loss of proteostasis, and inflammation.

A competing mechanistic view holds that endogenous synthesis from a protein-replete diet is sufficient in most healthy adults, that biomarker improvements may not translate into hard clinical endpoints, and that high antioxidant loads could blunt beneficial mitohormesis (the adaptive response in which low-level oxidative stress drives mitochondrial improvements with exercise). Both views are active in the current literature.

GlyNAC is a nutritional combination, not a single pharmacological compound. Pharmacological descriptors are most informative for its components: oral NAC reaches peak plasma concentration within 1–2 hours, has a terminal half-life of approximately 5–6 hours, and has a low oral bioavailability of roughly 4–10% due to extensive first-pass metabolism — sufficient for its role as a cysteine donor. Glycine is rapidly absorbed, has a plasma half-life on the order of 1–4 hours, and distributes broadly across tissues. Neither component is metabolized through CYP (cytochrome P450, a family of liver enzymes that metabolize many drugs) pathways in clinically meaningful ways at supplemental doses.

Historical Context & Evolution

GlyNAC has a relatively short but rapidly developing scientific history that draws on much older work on its components.

• NAC as a pharmaceutical: NAC was first introduced in the 1960s as a mucolytic for chronic respiratory disease and later became the standard intravenous and oral antidote for paracetamol overdose, where it works by restoring hepatic glutathione. Its role as a glutathione precursor has been well established since that era.

• Glycine in longevity research: Glycine has long been recognized as the simplest amino acid and a major substrate for collagen, glutathione, porphyrins, and creatine. Work in the early 2000s identified glycine availability — not just cysteine availability — as a co-limiting factor for glutathione synthesis in aging, challenging the assumption that NAC alone would correct the deficit.

• Origins of the GlyNAC concept: Dr. Rajagopal Sekhar at Baylor College of Medicine pioneered the combination after observing that supplementing NAC alone did not fully restore glutathione in older adults because glycine was also depleted. The first GlyNAC pilot studies in HIV patients began around the early 2010s, with results published from 2013 onward.

• Key milestones: A 36-week open-label trial in older adults (Kumar et al., 2021, Clin Transl Med) reported broad improvements across aging markers. A randomized, placebo-controlled trial (Kumar et al., 2023, J Gerontol A Biol Sci Med Sci) confirmed many of these findings over 16 weeks. A parallel mouse study reported a 24% increase in lifespan with lifelong GlyNAC supplementation. Independent work funded by Nestlé (Lizzo et al., 2022) tested lower doses for shorter durations and found benefit only in a subgroup with high baseline oxidative stress. Baylor College of Medicine holds intellectual property on GlyNAC, which has been licensed to Nestlé Health Science and marketed in the United States as Celltrient Cellular Protect — a structural conflict of interest noted here at first citation and revisited in the Conclusion.

• Current status: GlyNAC has moved from an academic concept into a commercial supplement category, but most of the supportive human evidence still originates from the Baylor group. Independent replication by unaffiliated centers is in early stages, and several relevant trials remain ongoing.

Expected Benefits

A dedicated search of the GlyNAC clinical trial program (pilot trial, RCT [randomized controlled trial, considered the gold standard study design], HIV trial, type 2 diabetes pilot, Nestlé-sponsored RCT) and the underlying NAC and glycine literature was performed before assembling this section. Benefits are framed for health- and longevity-oriented adults, particularly older adults with reduced glutathione reserves, not for the general population.

High 🟩 🟩 🟩

Restoration of Intracellular Glutathione

GlyNAC supplementation reliably restores intracellular GSH in older adults. The 16-week placebo-controlled RCT corrected red blood cell GSH deficiency to levels not significantly different from young adults, replicating the open-label pilot. This is the most consistently demonstrated effect across the GlyNAC trial program and is the prerequisite for downstream benefits.

Magnitude: Red blood cell GSH increased to levels comparable to healthy young adults (age 20–30) after 16 weeks of supplementation in the Baylor RCT.

Reduction in Oxidative Stress

Across all published GlyNAC trials in older adults, HIV patients, and type 2 diabetes patients, supplementation significantly lowered oxidative stress markers including TBARS (thiobarbituric acid reactive substances, a measure of lipid peroxidation), F2-isoprostanes, and protein carbonyls. The Nestlé-sponsored RCT in healthy older adults observed gains primarily in subjects with high baseline oxidative stress; the Baylor trials observed broad effects.

Magnitude: Oxidative stress markers (TBARS, F2-isoprostanes) decreased to levels not significantly different from young controls after 16 weeks of supplementation in the Baylor trials.

Medium 🟩 🟩

Improved Mitochondrial Fuel Oxidation

GlyNAC supplementation improves mitochondrial fuel oxidation in older adults and in patients with type 2 diabetes. In the T2D (type 2 diabetes) pilot, just 14 days of supplementation increased fasted MFO (mitochondrial fatty-acid oxidation) by 30%, decreased excessive mitochondrial glucose oxidation by 47%, and lowered fasting plasma free fatty acids by 25%.

Magnitude: ~30% increase in MFO and ~47% decrease in mitochondrial glucose oxidation in T2D patients after 14 days; corresponding shifts toward youthful patterns in older adults at 16 weeks.

Reduced Inflammation

The Baylor RCT in older adults reported significant reductions in inflammatory markers, contributing to lower “inflammaging” — the chronic low-grade inflammation associated with aging and many age-related diseases. The HIV trial reported similar inflammatory reductions in a population with chronically elevated inflammation.

Magnitude: Inflammatory marker reductions were statistically significant compared with placebo, with magnitudes varying by cytokine and trial.

Improved Insulin Sensitivity

GlyNAC supplementation reduces insulin resistance in healthy older adults, in patients with type 2 diabetes, and in HIV patients. In the T2D pilot, IR (insulin resistance, a condition where cells respond poorly to insulin’s effects on glucose handling) decreased by 22% after 14 days of supplementation.

Magnitude: Insulin resistance reduced by approximately 22% in T2D patients after 14 days; HOMA-IR (homeostatic model assessment of insulin resistance, a calculated measure derived from fasting glucose and insulin) reductions of similar magnitude in older adults at 16 weeks.

Improved Muscle Strength and Physical Function

In the 16-week Baylor RCT, GlyNAC supplementation improved gait speed, grip strength, and 6-minute walk test distance in older adults. These changes are clinically meaningful — gait speed in particular is an established predictor of mortality and disability in older populations. Confidence is limited by the very small per-arm sample size and single-group provenance of the trial.

Magnitude: Statistically significant improvements over placebo in gait speed, grip strength, and 6-minute walk distance in adults aged 65–80; precise effect-size ranges should be interpreted with caution given the small sample (n=12 per arm).

Low 🟩

Independent Replication at Lower Doses ⚠️ Conflicted

The Nestlé-sponsored RCT (Lizzo et al., 2022, n=114, 2 weeks) found that GlyNAC at three dose levels (2.4, 4.8, 7.2 g/day total) did not raise glutathione across the full healthy older-adult cohort, but subjects in the post-hoc subgroup with high baseline oxidative stress and low baseline GSH showed significant gains at the medium and higher doses. This contrasts with the broader response reported in the Baylor program.

Magnitude: Significant glutathione increases at medium and high doses in the high-oxidative-stress subgroup; no significant change in the overall trial population over 2 weeks.

Cognitive Improvement

The Baylor pilot and RCT reported significant improvements in cognitive test scores after GlyNAC. A 2023 mouse study from the same group showed corresponding restoration of brain glutathione, mitochondrial function, glucose uptake, and neurotrophic factors. The effect size in humans is suggestive but constrained by small sample sizes and limited cognitive batteries.

Magnitude: Cognitive test score improvements were statistically significant versus baseline, but effect sizes were modest and confidence is limited by sample size (n=12 per arm in the RCT).

Improved Body Composition

GlyNAC supplementation in the Baylor trials was associated with reductions in waist circumference and body fat in older adults, plausibly secondary to improved mitochondrial fuel oxidation and metabolic efficiency.

Magnitude: Waist circumference decreased significantly versus placebo in the 16-week RCT; specific fat-mass changes varied across trials.

Reduced Genomic Damage

GlyNAC supplementation reduced markers of genotoxicity in both the older-adult and HIV trials, suggesting improved DNA repair capacity or reduced DNA oxidation.

Magnitude: Genomic damage markers decreased significantly in the supplemented arm; specific magnitude varied by assay.

Improved Endothelial Function

Both the pilot and RCT reported improvements in endothelial function — an early marker of atherosclerosis — that are relevant to long-term cardiovascular health. Effect sizes outside research settings are uncertain.

Magnitude: Not quantified in available studies.

Modest Reductions in Blood Pressure

The Baylor RCT reported significant reductions in systolic blood pressure with GlyNAC. The mechanism is plausibly mediated through NAC’s vasodilatory effects via nitric oxide pathways, plus improved endothelial function.

Magnitude: Modest, clinically relevant reductions in systolic blood pressure compared with placebo in older adults; specific values varied by trial.

Speculative 🟨

Lifespan Extension in Humans

Mouse studies showed a 24% increase in median lifespan with lifelong GlyNAC supplementation, and the broad correction of aging hallmarks in human trials is mechanistically suggestive. However, no human longevity data exist, and rodent lifespan effects do not reliably translate to humans.

Cognitive Benefit in Mild Cognitive Impairment and Alzheimer’s Disease

Two early-phase trials at Baylor are investigating GlyNAC in mild cognitive impairment (NCT03493178) and Alzheimer’s disease (NCT04740580). The rationale is the cognitive improvements observed in healthy older adults plus mouse work showing restored brain glutathione and BDNF (brain-derived neurotrophic factor, a protein supporting neuron growth and survival). Efficacy data are not yet available.

Sex-Specific Cardiac Effects

A 2025 Baylor mouse study (Angelini et al.) reported that 12 weeks of dietary GlyNAC modestly improved cardiac diastolic function and exercise performance in old male mice but not in old females, with female mice unexpectedly showing worse exercise performance. Whether this sex-specific cardiac signal translates to humans is unknown.

Benefit-Modifying Factors

• Age: Benefits are most pronounced in adults with documented age-related glutathione deficiency. Young adults aged 20–30 in the Baylor trials had minimal baseline deficits and minimal change with supplementation. Adults aged 65–80 — including the oldest end of the target audience — showed the largest improvements across nearly all endpoints.

• Baseline oxidative stress and glutathione status: The Nestlé-sponsored RCT identified baseline oxidative stress and GSH status as the key determinant of response — only the high-oxidative-stress, low-GSH subgroup gained meaningfully at the doses tested. Individuals with greater baseline glutathione depletion appear to benefit more.

• Genetic polymorphisms: Variants in GCLC and GCLM (the catalytic and modifier subunits of glutamate–cysteine ligase, the rate-limiting enzyme for glutathione synthesis) influence baseline GSH synthesis. GSTM1 and GSTT1 null genotypes (relatively common variants of glutathione S-transferase, a detoxification enzyme family, that result in absent enzyme activity) are associated with elevated baseline oxidative stress and may amplify GlyNAC benefits.

• Sex-based differences: The published human GlyNAC trials enrolled both sexes but were not powered to detect sex-specific effects. The 2025 mouse study found cardiac and exercise responses that were beneficial in males but not in females, raising questions about whether the human response is uniform across sexes.

• Pre-existing conditions: Adults with type 2 diabetes, HIV, or other conditions associated with elevated oxidative stress and glutathione depletion have shown robust responses in pilot studies. Healthier adults with low baseline oxidative stress may experience smaller gains, mirroring the Nestlé trial subgroup pattern.

• Body composition and BMI: Most Baylor trial participants were overweight (BMI [body mass index, calculated as weight in kilograms divided by height in meters squared] generally above 27). Whether benefits are equally pronounced in lean older adults has not been directly tested.

Potential Risks & Side Effects

A dedicated search using clinical trial reports, FDA (U.S. Food and Drug Administration, the agency that regulates foods, drugs, biologics, and dietary supplements) prescribing data for IV NAC, drugs.com, Examine, and the published GlyNAC trials was performed before assembling this section. Most risks attributed to GlyNAC trace back to the NAC component, with a smaller contribution from glycine.

High 🟥 🟥 🟥

Gastrointestinal Discomfort

The most commonly reported side effects of GlyNAC are mild gastrointestinal symptoms, primarily attributable to the NAC component. Oral NAC can cause nausea, vomiting, diarrhea, abdominal cramping, and dyspepsia, particularly at initiation, with dose increases, or at the higher gram-scale doses used in the Baylor protocols. Symptoms typically resolve with continued use, dose titration, or co-administration with food.

Magnitude: Mild gastrointestinal symptoms reported in roughly 5–15% of NAC users and supplemented subjects in the GlyNAC RCTs; generally transient and dose-related.

Medium 🟥 🟥

Excessive Blood Pressure Reduction in People on Antihypertensives

NAC has vasodilatory properties via nitric oxide potentiation. Modest blood pressure reductions were observed as a benefit in the Baylor RCT, but for individuals already taking antihypertensive medications, the additive effect could result in symptomatic hypotension (abnormally low blood pressure that can cause dizziness or fainting).

Magnitude: Systolic blood pressure decreased by a clinically modest amount in the RCT; the magnitude of interaction with antihypertensive medications has not been formally studied.

Bronchospasm in Sulfite-Sensitive or Asthmatic Individuals

Inhaled NAC is a recognized trigger of bronchospasm (sudden tightening of the airway muscles) in individuals with asthma or sulfite sensitivity. Oral NAC carries a lower risk, but caution is warranted in susceptible individuals, particularly at the gram-scale daily doses used in GlyNAC protocols.

Magnitude: Not quantified in available studies for oral GlyNAC; established for inhaled NAC.

Low 🟥

Antiplatelet Effects and Bleeding Risk

NAC has mild antiplatelet activity that may theoretically increase bleeding risk when combined with anticoagulant or antiplatelet medications. The effect has not been quantified for oral GlyNAC at the supplemental doses used.

Magnitude: Not quantified in available studies.

Daytime Drowsiness from Glycine

Glycine acts as an inhibitory neurotransmitter at glycine receptors and as a co-agonist at NMDA (N-methyl-D-aspartate, an excitatory glutamate receptor in the brain) receptors. At gram-scale doses, particularly during the day, it may produce mild drowsiness or sedation. This effect is dose-dependent and is sometimes considered desirable when dosed at bedtime.

Magnitude: Not quantified in available studies.

Headache

Mild headache was reported in a minority of supplemented subjects in the Baylor RCTs, more commonly with rapid initiation or higher doses. The mechanism is unclear and may reflect transient shifts in cerebral redox state or osmotic effects from gram-scale amino acid loads. Symptoms typically resolve with continued use, dose reduction, or slower titration.

Magnitude: Not quantified in available studies.

Speculative 🟨

Theoretical Blunting of Exercise-Induced Adaptations ⚠️ Conflicted

High-dose antioxidant supplementation has been shown in NAC studies to blunt mitohormesis (the adaptive response in which low-level exercise-induced oxidative stress drives mitochondrial biogenesis and endurance gains). The Baylor GlyNAC trials nonetheless reported improved muscle strength and 6-minute walk distance in older adults, suggesting that benefits may outweigh blunting in deconditioned populations. The signal in trained athletes pursuing maximal endurance adaptations is uncertain.

Long-Term Safety Beyond Trial Durations

The longest published human GlyNAC trial covered 24 weeks. Multi-year safety data on continuous gram-scale dosing in older adults are not yet available, and theoretical concerns about chronic antioxidant supplementation interfering with redox signaling, immune function, or cancer surveillance remain open.

Unknown Effects in Pregnancy and Lactation

GlyNAC has not been studied in pregnant or lactating women. The effects of sustained glutathione modulation during pregnancy are unknown.

Risk-Modifying Factors

• Genetic polymorphisms: Pharmacogenetic variants affecting NAC metabolism (e.g., NAT2 [N-acetyltransferase 2, an acetylation enzyme that modifies xenobiotic handling]) and phase II conjugation enzymes may alter individual handling of large NAC doses, but specific high-risk variants have not been validated for oral GlyNAC at supplemental doses.

• Baseline blood pressure: Adults with low baseline blood pressure or those on antihypertensive medications are at higher risk for symptomatic hypotension due to NAC’s vasodilatory effects.

• Baseline biomarker levels: Adults with elevated baseline liver enzymes (ALT [alanine aminotransferase, an enzyme indicating liver health], AST [aspartate aminotransferase, an enzyme that rises with liver or muscle damage]), reduced kidney function (eGFR [estimated glomerular filtration rate, a measure of kidney filtration capacity] <60 mL/min/1.73 m²), or low platelet counts may be at greater risk for adverse responses to gram-scale chronic dosing; baseline labs help identify individuals who warrant closer monitoring or specialist input.

• Sex-based differences: The 2025 Baylor mouse study found cardiac responses that were beneficial in males but absent in females, with female mice showing decreased exercise performance on the supplemented diet. Whether this signal applies to humans is unknown; published human GlyNAC trials have not detected sex-specific adverse effects but were not powered to do so.

• Pre-existing conditions: Asthmatics (especially sulfite-sensitive), individuals with bleeding disorders or on anticoagulants, and people with severe renal disease (where the high amino acid load may stress nitrogen handling) face elevated risk. People with documented hypersensitivity to NAC or glycine should avoid GlyNAC.

• Age-related considerations: Older adults — the primary target population — tolerated supplementation well in trials lasting up to 24 weeks, including in adults aged 80. No age-specific risks were identified within the studied ranges, though polypharmacy in this group raises the practical likelihood of interactions.

Key Interactions & Contraindications

• Antihypertensive medications: NAC may potentiate blood pressure–lowering effects through nitric oxide pathways. Severity: caution. Consequence: symptomatic hypotension. Mitigation: monitor blood pressure closely during the first 2–4 weeks when combining with ACE inhibitors (angiotensin-converting enzyme inhibitors, a class of blood-pressure medications that relax vessels by blocking angiotensin formation; e.g., lisinopril, enalapril), ARBs (angiotensin II receptor blockers, a class of blood-pressure medications that block angiotensin’s effects on vessels; e.g., losartan, valsartan), calcium channel blockers, or other antihypertensives.

• Nitroglycerin and nitrate medications: NAC strongly potentiates the vasodilatory effect of nitroglycerin and related nitrates (e.g., isosorbide mononitrate, isosorbide dinitrate), potentially producing severe hypotension. Severity: absolute caution. Consequence: severe hypotension. Mitigation: avoid combination unless under direct cardiology supervision.

• Anticoagulant and antiplatelet drugs: NAC has mild antiplatelet activity. Severity: caution. Consequence: increased bleeding risk. Mitigation: discuss with the prescriber when combined with warfarin, direct oral anticoagulants (e.g., apixaban, rivaroxaban), aspirin, clopidogrel, or other antiplatelets; consider stopping at least 2 weeks before elective surgery.

• Clozapine: Glycine acts as an NMDA-receptor co-agonist and may reduce the antipsychotic efficacy of clozapine (an atypical antipsychotic used in treatment-resistant schizophrenia). Severity: contraindication. Consequence: loss of psychiatric symptom control. Mitigation: do not co-administer; this is an established consideration in the schizophrenia glycine literature.

• Cytotoxic chemotherapy: Glutathione’s antioxidant activity could theoretically blunt the oxidative cytotoxicity of platinum agents (a class of DNA-crosslinking chemotherapy drugs; e.g., cisplatin, carboplatin), anthracyclines (a class of chemotherapy drugs that intercalate DNA and generate free radicals; e.g., doxorubicin), and alkylators (a class of chemotherapy drugs that attach alkyl groups to DNA, blocking replication; e.g., cyclophosphamide). The American Society of Clinical Oncology (ASCO, a professional society of practicing oncologists) guideline on chemotherapy-induced peripheral neuropathy recommends against using glutathione during neurotoxic chemotherapy. ASCO is a professional organization whose practicing-oncologist members derive direct revenue from delivering and managing chemotherapy regimens — a structural conflict of interest noted here at first citation and revisited in the Conclusion. Severity: caution to absolute caution. Consequence: potential reduction in anticancer efficacy. Mitigation: avoid GlyNAC during active cytotoxic treatment unless directed by an oncologist.

• Activated charcoal: Activated charcoal can bind NAC and reduce absorption. Severity: minor. Consequence: reduced NAC bioavailability. Mitigation: separate by at least 2 hours.

• Other antioxidant supplements (additive effect): Alpha-lipoic acid, vitamin C, vitamin E, selenium, sulforaphane, and milk thistle (silymarin) all increase or spare glutathione. Combinations are common in longevity stacks but raise the additive-antioxidant load and the theoretical chance of blunting exercise-induced adaptations.

• Blood pressure–lowering supplements (additive effect): Magnesium, CoQ10 (coenzyme Q10, a compound involved in cellular energy production and a mild vasodilator), fish oil (omega-3), beetroot/nitrate supplements, and garlic extract may produce additive blood-pressure reductions when stacked with GlyNAC due to NAC’s vasodilatory effect.

• Iron supplements: NAC can chelate certain metal ions; clinically significant interactions with oral iron supplements have not been established but separating dosing by 2 hours is a reasonable precaution.

• Populations to avoid this intervention:

  • Adults on clozapine for treatment-resistant schizophrenia (contraindication via the glycine component).
  • Adults receiving active cytotoxic chemotherapy with platinum agents, anthracyclines, or alkylators within the prior 7 days or planned within the next 7 days (caution to contraindication).
  • Adults taking nitroglycerin or other nitrate medications (absolute caution unless under cardiology supervision).
  • Adults with severe asthma — particularly documented sulfite-induced bronchospasm or FEV1 (forced expiratory volume in one second, a key spirometry measure of airflow) <70% of predicted — without specialist input.
  • Adults with severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR <30 mL/min/1.73 m²) for chronic gram-scale dosing.
  • Adults scheduled for elective surgery within 2 weeks (discontinue due to potential antiplatelet effect).
  • Pregnant or breastfeeding women (insufficient safety data).

Risk Mitigation Strategies

• Start low and titrate slowly: Begin at roughly half the target dose (e.g., 1–2 g each of glycine and NAC daily) and increase to the full target dose over 2–4 weeks. Mitigates: gastrointestinal discomfort, headache, and excessive blood pressure reduction.

• Take with food: Co-administer GlyNAC with the largest meal of the day. Mitigates: nausea and dyspepsia.

• Split the daily dose: Divide the total daily dose into two servings (morning and evening) to improve gastrointestinal tolerability and maintain more stable amino acid availability. Mitigates: gastrointestinal symptoms; supports evening sleep benefit from glycine.

• Monitor blood pressure during initiation: Check blood pressure at home weekly during the first 4 weeks for adults on antihypertensives. Mitigates: symptomatic hypotension.

• Discontinue 2 weeks before elective surgery: Stop GlyNAC at least 14 days before any planned surgical procedure. Mitigates: theoretical antiplatelet bleeding risk.

• Pause around active chemotherapy: Stop GlyNAC at least 7 days before, during, and 7 days after each cytotoxic chemotherapy cycle unless an oncologist directs otherwise. Mitigates: blunting of cytotoxic efficacy.

• Time large antioxidant doses away from training: When mitochondrial adaptation to endurance training is a primary goal, avoid taking the day’s full antioxidant dose within 1–2 hours of the workout. Mitigates: blunted training adaptation.

• Periodic safety chemistry: Annual basic chemistry (CMP [comprehensive metabolic panel, a blood test measuring liver enzymes, kidney function, electrolytes, and glucose], complete blood count) is a low-cost safeguard for adults on chronic gram-scale dosing for more than 12 months. Mitigates: undetected end-organ effects.

• Use third-party-tested products: Choose glycine and NAC products that carry independent quality testing (e.g., USP [United States Pharmacopeia, a non-profit organization that sets quality standards for medicines and supplements], NSF International, or ConsumerLab seals). Mitigates: under- or over-dosing and contamination.

Therapeutic Protocol

The most well-studied protocol is the body-weight-based approach used in the Baylor College of Medicine trials led by Dr. Rajagopal Sekhar. A second, lower-dose approach was tested by the Nestlé-sponsored trial. Practitioners frame these as alternatives, not as sequential steps.

• Standard high-dose protocol (Baylor): 100 mg/kg/day of glycine and 100 mg/kg/day of NAC, divided into two doses with meals. For a 70 kg (154 lb) adult, this is approximately 7 g of each per day. The Baylor pilot used 24 weeks; the RCT used 16 weeks.

• Lower-dose protocol (Nestlé): Total daily doses of glycine + NAC of 2.4, 4.8, or 7.2 g (1:1 ratio), tested in healthy older adults for 2 weeks. Subgroup analysis suggested medium and high doses were effective in those with elevated baseline oxidative stress.

• Practical starting dose: Many practitioners start at 1–2 g each of glycine and NAC daily, taken with food, and titrate to the target dose over 2–4 weeks.

• Best time of day: GlyNAC is typically taken morning and evening with meals. Glycine’s mild calming effect makes evening dosing attractive when sleep support is desired.

• Half-life and dosing frequency: Oral NAC has a terminal half-life of approximately 5–6 hours and low oral bioavailability (~4–10%) but is sufficient as a cysteine donor for glutathione synthesis. Glycine has a plasma half-life on the order of 1–4 hours and distributes broadly across tissues. Twice-daily dosing was used in the Baylor trials; once-daily dosing has not been formally tested for the gram-scale protocol.

• Single vs. split dosing: All Baylor trials used split (twice-daily) dosing. Split dosing is also expected to improve gastrointestinal tolerability versus single large doses.

• Genetic polymorphisms influencing protocol or dose: No specific pharmacogenetic testing is currently indicated. Adults with known GSTM1 or GSTT1 null genotypes (variants of glutathione S-transferase, a detoxification enzyme family, resulting in absent enzyme activity) may have higher baseline oxidative stress and could potentially benefit more. APOE4 (a variant of the apolipoprotein E gene linked to higher Alzheimer’s disease risk), MTHFR (a variant of methylenetetrahydrofolate reductase, an enzyme central to folate and methylation metabolism, that may slow homocysteine clearance), and COMT (a variant of catechol-O-methyltransferase, an enzyme that breaks down catecholamines and influences dopamine and estrogen turnover) are pharmacogenetically relevant variants that may modulate response, but no GlyNAC-specific dose adjustments are established.

• Sex-based differences: Published human trials used the same body-weight-based dosing for both sexes. The 2025 mouse study suggesting reduced cardiac and exercise benefit in old female mice has not been replicated in humans; no sex-specific dose adjustment is currently warranted.

• Age-related considerations: The strongest evidence supports use in adults aged 60 and older, where baseline glutathione deficiency is most pronounced. Younger adults with adequate glutathione status are likely to see smaller biochemical changes. Adults at the older end of the target audience (75–85) tolerated standard dosing well in published trials, with slower titration recommended.

• Baseline biomarker levels: Where feasible, measuring baseline red blood cell GSH or oxidative stress markers (F2-isoprostanes, TBARS) can identify likely responders and provide a follow-up endpoint. Subgroup analyses suggest the highest responders are those with elevated baseline oxidative stress and reduced GSH.

• Pre-existing conditions: Type 2 diabetes patients showed rapid mitochondrial and metabolic improvements within 14 days. HIV patients showed broad benefits in the open-label trial. Adults with severe renal or hepatic impairment require individualized dosing and specialist input.

Discontinuation & Cycling

• Lifelong vs. short-term: Current evidence supports GlyNAC as a long-term, ongoing intervention. The Baylor pilot demonstrated that benefits regressed within 12 weeks of stopping, indicating that continuous use is required to sustain effects.

• Withdrawal effects: No physical-dependence withdrawal is described. The reversal of biochemical and functional gains observed after discontinuation reflects loss of the supplemented substrate rather than a rebound phenomenon.

• Tapering protocol: Tapering is not required for safety. Supplementation can be stopped abruptly without known adverse effects.

• Cycling: No evidence supports cycling GlyNAC for efficacy. Continuous daily dosing appears most appropriate based on the existing pilot and RCT data, in which benefits faded after discontinuation. Cycling around training blocks (lower doses during peak endurance training weeks) may be considered when blunting of mitochondrial adaptation is a concern.

Sourcing and Quality

• Form selection: GlyNAC is available as a combined branded supplement (most prominently Celltrient Cellular Protect from Nestlé Health Science, the licensed commercial product based on the Baylor patent) and as separate glycine and NAC capsules or powders. At the gram-scale doses used in the Baylor trials, separate bulk powders are typically the most cost-effective option.

• Third-party testing: Choose products that carry independent third-party certification — USP, NSF International, or ConsumerLab seals — to verify label accuracy, purity, and absence of heavy metals. ConsumerLab’s NAC review identified label-accuracy and contamination concerns in some products.

• NAC form: Standard N-acetyl-L-Cysteine is the form used in all published GlyNAC clinical trials. Alternative forms such as NAC ethyl ester (NACET) are marketed as having higher bioavailability but have not been studied in GlyNAC protocols and are not interchangeable in the context of current evidence.

• Glycine form: L-Glycine is the only relevant form and is widely available. Glycine is sweet-tasting, dissolves easily in water, and shows minimal quality variation between manufacturers.

• Reputable brands: Thorne Research, Pure Encapsulations, Life Extension, NOW Foods, and Jarrow Formulas are widely cited reputable manufacturers for individual glycine and NAC products. For combined GlyNAC formulations, Celltrient is the licensed commercial product; several smaller manufacturers also offer combined formulations of varying quality.

• Storage: Both glycine and NAC powders are stable when stored cool, dry, and away from light. NAC has a characteristic sulfur smell at higher doses; product odor is not by itself an indicator of degradation.

Practical Considerations

• Time to effect: The Baylor RCT observed some changes (oxidative stress, glutathione) by 2 weeks of supplementation, with most physical and metabolic benefits emerging by 16 weeks. The T2D pilot showed mitochondrial and insulin sensitivity improvements within 14 days. Subjective benefits (energy, cognitive clarity, sleep) typically take 4–8 weeks to notice.

• Common pitfalls:
  • Dosing too low: many off-the-shelf GlyNAC supplements provide only 500–1,000 mg of each ingredient per serving, far below the gram-scale doses used in the Baylor trials (~7 g each for a 70 kg adult).
  • Skipping titration: starting at full dose rather than titrating up gradually often produces unnecessary nausea and discomfort.
  • Expecting fast results on functional endpoints: while some biomarkers shift within 2 weeks, many functional benefits take 3–4 months to fully manifest.
  • Stopping prematurely: benefits regressed within weeks to months after discontinuation in the Baylor pilot.
  • Treating GlyNAC as interchangeable with NAC alone: the clinical rationale for the combination depends on supplying both co-limiting substrates.

• Regulatory status: Glycine and NAC are sold as dietary supplements in the United States and most jurisdictions. The FDA briefly questioned NAC’s status as a dietary supplement in 2020 due to its earlier approval as a prescription drug, but as of 2023, the agency has exercised enforcement discretion allowing NAC to remain available as a supplement.

• Cost and accessibility: At the Baylor trial dose (approximately 7 g each per day for a 70 kg adult), GlyNAC costs roughly US $30–60 per month when buying bulk powders of glycine and NAC separately. Pre-formulated combined products tend to be more expensive and frequently provide lower per-serving doses, raising effective monthly cost at clinical-trial dosing.

Interaction with Foundational Habits

• Sleep: Glycine has established mild sleep-onset and sleep-quality effects in small randomized trials at doses of around 3 g before bed. NAC does not appear to disrupt sleep. Direction: indirect, mildly potentiating for sleep when the evening portion of GlyNAC is dosed before bed. Practical consideration: split dosing so the evening serving is taken roughly 30–60 minutes before bedtime for individuals seeking sleep support.

• Nutrition: GlyNAC does not deplete specific nutrients. Dietary protein supplies baseline glycine and cysteine; adults with very low protein intake may have greater glutathione deficiency and potentially greater benefit. Cruciferous vegetables (broccoli, broccoli sprouts, kale) provide sulforaphane, which raises tissue GSH via Nrf2 activation. GlyNAC can be taken with or without food; taking it with the largest meal of the day generally improves tolerability. Direction: directly potentiating; mechanism: substrate provision.

• Exercise: Acute high-intensity exercise transiently lowers tissue GSH and elevates oxidative stress; this is part of the adaptive (mitohormetic) signal that drives improved fitness. Heavy antioxidant dosing within 1–2 hours of training has been shown in NAC studies to blunt mitochondrial biogenesis and endurance gains. The Baylor GlyNAC trials nonetheless showed improved muscle strength and walking performance in older adults, suggesting that benefit-to-blunting balance favors deconditioned populations. Direction: potential blunting if timed around training; practical consideration: when endurance adaptation is a priority, time the day’s full antioxidant dose at least 2–3 hours away from training sessions.

• Stress management: Chronic psychological stress depletes glutathione via sustained cortisol output and oxidative load. Glycine’s inhibitory neurotransmitter activity may modestly support a calmer baseline state. Practices that modulate the autonomic nervous system — slow breathwork, meditation, sauna — have been associated in small studies with improved antioxidant markers. Direction: indirectly potentiating; mechanism: reduced sympathetic and oxidative load.

Monitoring Protocol & Defining Success

Functional-medicine practitioners typically obtain baseline laboratory testing before initiating GlyNAC to identify deficiency, exclude contraindications, and provide a comparison point. Ongoing monitoring is performed at 12 weeks of supplementation and then every 6–12 months while on chronic dosing, with annual safety chemistry (ALT, AST, eGFR, complete blood count) for adults on gram-scale dosing for more than 12 months.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Red blood cell (RBC) reduced glutathione	>900 µM (functional medicine target); 4.0–6.0 mmol/L (whole-blood reference)	Best available marker of intracellular GSH (glutathione, the body’s main intracellular antioxidant) status; primary target of GlyNAC	Specialty labs only; not part of standard panels. Conventional reference range generally 600–1,200 µM.
GSSG/GSH ratio	<0.10 (lower is better)	Reflects redox balance between oxidized and reduced glutathione	Requires careful sample handling; specialty labs. GSSG is the oxidized form of GSH.
F2-isoprostanes (urine)	<2.0 ng/mg creatinine	Gold-standard marker of in vivo lipid peroxidation; falls with effective antioxidant therapy	Spot-urine; specialty labs.
hs-CRP	<1.0 mg/L (functional); <3.0 mg/L (conventional cardiovascular cutoff)	Tracks systemic inflammation	hs-CRP (high-sensitivity C-reactive protein) is a sensitive blood marker of systemic inflammation. Avoid measurement during acute illness.
Fasting glucose	70–85 mg/dL (functional); 70–99 mg/dL (conventional)	Metabolic baseline relevant for diabetes/prediabetes use	Standard panel; fasting 10–12 hours required.
Fasting insulin	2.0–5.0 µIU/mL	Assesses insulin resistance improvement	Conventional range up to 25 µIU/mL; fasting required. Pair with glucose for HOMA-IR.
HOMA-IR	<1.5 (functional); <2.5 (conventional cutoff)	Calculated measure of insulin resistance; useful when metabolic improvement is a goal	HOMA-IR (homeostatic model assessment of insulin resistance, calculated from fasting glucose and insulin).
ALT	10–25 U/L (male), 10–20 U/L (female)	Monitors liver safety during chronic supplementation	ALT (alanine aminotransferase, an enzyme indicating liver health). Conventional upper limit ~40–56 U/L.
AST	10–25 U/L (male), 10–20 U/L (female)	Complements ALT for liver and muscle injury detection	AST (aspartate aminotransferase, an enzyme that rises with liver or muscle damage). Conventional upper limit ~40 U/L.
Creatinine and eGFR	Creatinine 0.7–1.2 mg/dL (male), 0.5–0.9 mg/dL (female); eGFR >90 mL/min/1.73 m²	Monitors kidney function during gram-scale amino acid intake	eGFR (estimated glomerular filtration rate, a measure of kidney filtration capacity).
GGT	10–30 U/L	Marker of oxidative stress and hepatobiliary health	GGT (gamma-glutamyl transferase, an enzyme involved in extracellular glutathione metabolism). Conventional upper limit ~65 U/L.
Blood pressure	<130/80 mmHg	Tracks the modest antihypertensive effect of GlyNAC and detects excessive reduction	Home cuff measurements during initiation are useful for adults on antihypertensives.

Qualitative markers tracked alongside laboratory data:

• Daytime energy and exercise tolerance
• Cognitive clarity, working memory, and processing speed (especially in older adults)
• Sleep quality, particularly with evening glycine dosing
• Grip strength (inexpensive home dynamometers available)
• Gait speed (timed-walk tests over 4–10 metres)
• Recovery time after intense exertion
• Frequency of common infections (as a coarse immune marker)

Emerging Research

• Alzheimer’s disease trial: NCT04740580 is an Early Phase 1 trial at Baylor College of Medicine (n=52, recruiting) testing GlyNAC versus alanine placebo in Alzheimer’s disease, with brain glutathione, brain metabolism, inflammation, and cognition endpoints.

• Mild cognitive impairment trial: NCT03493178 is an Early Phase 1 trial (n=60) of glycine plus NAC versus alanine in mild cognitive impairment, with 12 weeks of supplementation followed by a 12-week withdrawal phase.

• Postoperative oxidative stress and chronic pain: NCT06083480 is a Phase 4 trial (n=148) studying whether GlyNAC reduces perioperative oxidative stress and prevents chronic pain following total knee arthroplasty, representing a novel application of GlyNAC outside the aging context.

• Sex-specific cardiac response: A 2025 mouse study from a Baylor-affiliated cardiovascular group (Angelini et al., 2025) reported that 12 weeks of dietary GlyNAC modestly improved diastolic function and exercise performance in old male mice but not in old females, with female mice showing reduced exercise performance — a finding that could refine future dosing or eligibility recommendations if it translates to humans.

• Spinal cord injury and skeletal muscle protection: A 2024 rat study (Xu et al., 2024) reported that GlyNAC improved motor and sensory recovery, raised tissue GSH, and reduced oxidative damage after spinal cord injury — early preclinical evidence for a novel, non-aging application.

• Independent replication need: The most important emerging development is the need for independent replication of the Baylor findings by unaffiliated research groups. The Nestlé-sponsored RCT (Lizzo et al., 2022) provided partial independent data at lower doses and shorter duration and found benefit only in a subgroup with high baseline oxidative stress. Larger, longer, multi-center placebo-controlled trials in diverse populations would substantially strengthen or weaken the broad benefit case.

• Areas of future research that could change current understanding:

  • Could weaken the case: Large independent placebo-controlled trials in healthy adults (rather than in populations with documented oxidative stress) that fail to replicate the broad endpoint improvements; long-term outcome trials that show no effect on incident disease or mortality; and trials that confirm meaningful blunting of exercise-induced mitochondrial adaptation when GlyNAC is dosed around training.
  • Could strengthen the case: Independent replication of the Baylor 16- and 24-week findings; cognitive benefit in mild cognitive impairment and Alzheimer’s disease (NCT03493178, NCT04740580); demonstration of improvements in hard cardiovascular or metabolic endpoints; and successful sex-stratified analyses that clarify whether the male-favored cardiac signal seen in mice generalizes to humans.

Conclusion

GlyNAC is a fixed combination of two amino acids — glycine and N-acetylcysteine — taken to restore the body’s main intracellular antioxidant by supplying both of its co-limiting building blocks. Across a small but consistent series of trials in older adults and in people with type 2 diabetes or HIV, the combination has reliably restored glutathione, lowered oxidative stress, and improved a range of aging-related markers including mitochondrial function, inflammation, insulin sensitivity, and physical performance. The safety profile in trials lasting up to six months has been favorable, with mild gastrointestinal symptoms as the most common side effect.

Several considerations temper the enthusiasm. The most striking human findings come from a single research group at Baylor College of Medicine, which holds the underlying intellectual property licensed to a major nutrition company — a structural conflict of interest that warrants weight. The major oncology society’s recommendation against glutathione during neurotoxic chemotherapy similarly comes from a body whose members derive direct revenue from those treatments — a parallel structural bias. An independent trial at lower doses and shorter duration found benefit only in a subgroup with high baseline oxidative stress, long-term safety beyond about six months is not established, and a recent animal study raises a sex-specific question about responses in females.

The evidence base is therefore promising but narrow: a coherent biochemical and functional signal in older adults with elevated oxidative stress, set against single-laboratory provenance, short follow-up, an only partially replicating independent trial, and an unresolved preclinical sex-specific signal.

Top - Benefits - Risks - Protocol